| 2019-09-18 |
188 |
Order on Motion to Dismiss |
21 6,340,475; 6,635,280; 6,488,962; and 6,723,340. Lupin had successfully designed around the
… 16 for the patent barrier remains. New brand-drug applicants must list the patents (if any) covering…brand drug, that the relevant patents have expired, or that such patents are invalid or will not be
… or invalidity against the four relevant patents: U.S. Patent Nos.
…infringe the patents
4 because it designed around the patents using a |
External link to document |
| 2019-09-18 |
347 |
Order on Motion to Certify Class |
10 6,340,475; 6,635,280; 6,488,962; and 6,723,340. Assertio Therapeutics, Inc. (then owner of
… or invalidity against the four relevant patents: U.S. Patent Nos.
…analogous anticompetitive behavior, patent misuse, by holding a patent
…from an alleged reverse-payment settlement of a patent
17 infringement…restating. This case arises from a perversion of the patent and pharmaceutical-
|
External link to document |
| 2019-09-18 |
537 |
Order on Motion for Partial Summary Judgment AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal |
,488,962, which expired in June 2020, and No. 6,723,340, which will expire in October 2021.
…’475, ’280, and ’962 patents (it also asserted but later dropped the ’340 patent).
…This argument runs afoul of patent fundamentals. True, we presume a patent’s validity. See
…within the scope of the patent. The royalty payment from the licensee to the patent owner
… 19 In a secret pharmaceutical-patent infringement settlement agreement, concealed from |
External link to document |
